Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
Veracyte secured Medicare coverage for its TrueMRD Monitoring Test in muscle-invasive bladder cancer, marking the first coverage decision for its whole-genome sequencing MRD platform. The test will launch commercially on June 1, 2026, allowing clinicians to order it for recurrence monitoring following curative treatment.
Key figures
- Drug Name
- TrueMRD Monitoring Test
- Mibc recurrence rate
- 50%
- Mibc diagnoses annual
- 85000
- Commercial launch date
- June 1, 2026
- Earlier detection days
- 131
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.